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Abstract
Background: Homocysteine has been postulated as a novel, potentially reversible risk factor for osteoporosis and
related fractures. We evaluated whether homocysteine-lowering therapy with B-vitamins in patients with
symptomatic cerebrovascular disease reduced the incidence of osteoporotic fractures.
Methods: VITAmins To Prevent Stroke (VITATOPS) was a prospective randomised double-blind placebo-controlled
trial in which 8,164 patients with recent (within 7 months) stroke or transient ischemic attack were randomly
allocated to double-blind treatment with one tablet daily of either placebo (n = 4,075) or B-vitamins (folic acid
2 mg, vitamin B6 25 mg, vitamin B12 500 μg; n = 4,089). Patients were reviewed every six months. Any osteoporotic
fracture and osteoporotic hip fractures were secondary outcome events, and were reviewed by a masked
adjudication committee. Analysis was by intention to treat. Logistic regression was used to identify independent
predictors of fracture.
Results: Participants had a mean age of 62.6 years (SD 12.5 years) and 64% were male, 42% of Western European
descent and 75% were functionally independent (Oxford Handicap Scale of two or less). After a median duration of
2.8 years therapy and 3.4 years follow-up, there was no significant difference in the incidence of any osteoporotic
fracture between participants assigned B-vitamins (67 [1.64%]) and placebo (78 [1.91%]; risk ratio [RR] 0.86, 95%
confidence interval [CI] 0.62-1.18) or the incidence of hip fractures (34 [0.83%] B-vitamins vs. 36 [0.88%] placebo; RR
0.94, 95% CI 0.59-1.5). There was no significant impact of B-vitamin therapy on time to first fracture. Baseline
homocysteine levels did not predict any osteoporotic fracture (p =0.43). Independent predictors of any osteoporotic
fracture were female sex, age > 64 years, Western European ethnicity and use of anti-osteoporosis medication at
randomization (all p < 0.01).
Conclusions: Once daily treatment with B-vitamins had no effect on incidence of osteoporotic fractures during a
median of 3.4 years follow-up in patients with cerebrovascular disease. A modest effect of B-vitamin therapy is not
excluded due to the low numbers of fracture outcome events.
Trial registration: Clinicaltrials.gov number: NCT00097669 and isrctn.org number: ISRCTN74743444.
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Background
Osteoporosis is a widely prevalent, age-related skeletal
disorder characterized by compromised bone strength
and an increased risk of bone fracture [1,2]. Osteoporotic
fractures, particularly hip (femoral neck) fractures that
usually require hospitalisation and surgery, are frequently
associated with poor outcomes including the need for
institutional care and death [1,3]. Simple interventions
that can prevent or delay the onset of osteoporosis and its
complications are needed to stem the projected increase
in the burden of osteoporosis due to the increasing age
and other demographic changes in the population [4,5].
An increased plasma concentration of total homocysteine
(tHcy) has been postulated as a novel, potentially treatable
risk factor for osteoporotic fractures, including hip fractures
[2,6-8]. In one prospective population-based study, the
highest quartile of tHcy was associated with a two-fold
increase in risk of fracture (risk ratio [RR] 1.9, 95% con-
fidence interval [CI] 1.4-2.6), and the association was
continuous; with each standard deviation (SD) increase
in tHcy, the risk of fracture increased by 30% (RR 1.3, 95%
CI 1.1-1.5) [9]. These findings have been validated in other
populations [10,11]. Further, the strength of the association
between high tHcy and fracture risk (RR 1.9 for every SD
increase) is of similar magnitude to that attributable to
other accepted risk factors for hip fracture such as age
over 75 years (RR 2.3), falls in the previous year (1.9), low
bone density (1.6) and current smoking (1.6) [9]. Several
biological mechanisms have been postulated to account
for this association but it is still uncertain whether the
association is causal, confounded or biased due to reverse
causality [2,6,12-14]. As raised tHcy can be lowered with
B-vitamin therapy, [15,16] it is possible to determine
whether tHcy is a causal risk factor for bone fracture
by means of randomised controlled trials (RCTs) of
B-vitamins vs. placebo. Four RCTs have examined the
effect of B-vitamins on biomarkers of bone turnover but
have been limited by the use of surrogate outcomes for
fracture risk, lack of statistical power due to the inclusion
of small numbers of subjects and/or use of healthy
volunteers [17-20]. Two RCTs of B-vitamins on bone
fracture risk have produced conflicting results. The largest,
involving 5522 patients, failed to show any significant
impact of B-vitamins on fracture incidence despite a 3.3
μmol/L lower tHcy and a mean follow-up of five years
[21,22]. The only positive intervention study to date was
undertaken in 628 elderly Japanese patients with significant
residual hemiplegia at least one year following stroke [23].
Those treated with combination folate and vitamin B12
had a 75% reduction (adjusted RR 0.24, 95% CI 0.11-0.53)
in the incidence of fracture at two years. However, the
study population was highly selected and characterized by
severe disability, very high homocysteine concentrations
(mean 19.9 μmol/L), and an unusually high fracture rate in
the control group, approximately 10 times the rate found
in the average Japanese population of the same age [24].
In light of the uncertainty surrounding the role of tHcy
in the pathogenesis of osteoporosis and bone fracture, we
prospectively examined the occurrence of any osteoporotic
fracture and osteoporotic hip fractures in the VITAmins
TO Prevent Stroke (VITATOPS) trial of patients with
recently symptomatic cerebrovascular disease treated with
either B-vitamins or placebo.
Methods
The rationale, methods, CONSORT flowchart and primary
results of the VITATOPS trial have been published [25,26].
In summary, VITATOPS was an investigator-led, prospect-
ive, randomised, double-blind, placebo-controlled trial
in which 8164 patients with recent (within seven months)
stroke or transient ischemic attack (TIA) were recruited
between November 19 1998 and December 31 2008, and
randomly assigned to receive either one tablet daily of
B-vitamins (folic acid 2 mg, vitamin B6 25 mg, vitamin
B12 500 μg) or matching placebo. Final follow-up was 30
June 2009 ensuring a minimum six months and up to
10.5 years on study medication.
The study was conducted in accordance with principles
of good clinical practice and the Declaration of Helsinki,
and received ethics approval in the United Kingdom from
the Multicentre Research Ethics Committee for Scotland A,
in New Zealand from the Multi-region Ethics Committee
and from local research ethics committees applicable to
each participating centre. A full list of the 127 participating
centres is available in an additional file [see Additional
file 1]. All patients provided written informed consent
before enrolment.
Demographic and clinical characteristics of the partici-
pants recorded at baseline included; age, sex, ethnicity (of
participants and their parents and grandparents), clinical
details of the qualifying cerebrovascular event, current
medications, past medical history (major vascular events,
revascularisation procedures, depression), vascular risk
factors (hypertension, smoking, hypercholesterolaemia,
diabetes mellitus, ischaemic heart disease, atrial fibrilla-
tion, peripheral artery disease), alcohol intake, Oxford
Handicap Score, Hospital Anxiety and Depression Score,
and Mini Mental State Examination score. Cox’s propor-
tional hazards models were used to adjust for differences
in baseline variables.
Investigators were encouraged but not obligated to take
blood samples from study participants who consented to
these optional tests, to measure blood concentrations of
tHcy, red cell folate and vitamin B12 at study entry and/or
at the time of their final follow-up visit. Fasting plasma
tHcy was measured by high-performance liquid chroma-
tography, on venous blood samples collected after an
overnight fast.
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The primary outcome measure for the main VITATOPS
study was the composite of any stroke, myocardial infarc-
tion or death due to vascular causes. In this substudy the
main outcome measure was occurrence of any clinically
apparent osteoporotic fracture. Osteoporotic hip fractures
and time till first fracture were secondary outcome
measures. Non-osteoporotic fractures were excluded
from analysis.
Patients were reviewed six-monthly and data on clinical
fracture outcomes were based on information obtained
from clinical history, radiology reports, hospital discharge
reports and health records. All hospitalisations including
those for fracture were recorded prospectively, and from
2004 (following publication of the potential association
between homocysteine and fracture risk [6]) until the end
of the trial in June 2009 all clinically apparent fractures
whether hospitalised or not, were recorded prospectively.
A masked adjudication committee audited all frac-
tures. Fractures were classified as osteoporotic if they
were reported to be osteoporotic by the investigator; and
involved the hip (neck of femur), wrist (distal radius)
or spine (vertebral), or occurred spontaneously or in
the context of minor trauma; and if there was no other
apparent cause (e.g. severe trauma, metastatic cancer).
The primary statistical analysis for this substudy was an
intention-to-treat analysis of the incidence of any osteo-
porotic fracture in the placebo and B-vitamin treatment
groups over the duration of follow-up. This was added to
the pre-established analysis plan in 2004. A secondary per
protocol on-treatment analysis would exclude any patients
found to be invalid after randomisation or who had cross-
over in treatment during follow-up.
The event rates were calculated as the number of events
that occurred during the follow-up period divided by
the total number of patients randomised. The risk ratios
(treatment/placebo) of the fracture rates in the treatment
and placebo groups and their 95% confidence intervals
were calculated to describe the treatment effect. We
used Kaplan-Meier methods to construct cumulative
time-to-event curves for the two groups and the main
comparison was based on a log-rank test.
We did stepwise logistic multivariable regression analysis
to determine the independent risk factors for osteoporotic
fracture in the study population.
Two sided significance tests were used throughout and
a two-sided p-value < 0.05 was considered significant.
Results
Full details of baseline demographic data, clinical charac-
teristics, laboratory results, adherence to therapy, follow
up rates and primary (non-fracture) outcome data have
previously been published [26]. Participants had a mean
age of 62.6 years (SD 12.5 years) and 64% were male, 42%
of Western European descent and 75% had an Oxford
Handicap Scale of two or less indicating either no lifestyle
restrictions or ability to manage without assistance.
At randomisation, 4089 participants were allocated to
B-vitamins and 4075 to placebo. A total of 579 participants
(7.1% B-vitamins, 6.8% placebo, p = 0.39) were taking
medications for prevention or treatment of osteoporosis.
These were predominantly calcium supplements - alone
(n = 462) or in combination with other medications (n = 41).
The remainder were vitamin D (n = 24), bisphosphonates
(n = 24), hormone replacement therapy (n = 18) or a com-
bination of these (n = 10).
Follow-up
Follow-up continued for a median duration of 3.4 years
per person (Inter Quartile Range [IQR] 2.0-5.5 years, range
0–9 years) with mean adherence to study treatment of
2.8 years (IQR 1.2-4.7 years). The longer duration of follow-
up (0.6 years) reflects those patients who discontinued
trial drugs but agreed to continue with follow-up.
A total of 425 patients (5.2%) withdrew from study
follow-up prior to the inclusion of fractures as a specified
reportable outcome event in 2004.
Osteoporotic fracture incidence
At the end of the trial, any clinically apparent osteoporotic
fracture occurred in 67 (1.64%) participants assigned
B-vitamins and 78 (1.91%) assigned to placebo (RR 0.86,
95% CI 0.62-1.18); and hip fractures occurred in 34
Table 1 Osteoporotic fracture outcomes according to treatment group
Osteoporotic fractures B-Vitamins Placebo Relative risk p-value
(n = 4089) (n = 4075) (95% confidence interval) (log-rank test)
N (%) N (%)
Any 67 (1.6) 78 (1.1) 0.86 (0.62,1.18) 0.32
Hip 34 (0.8) 36 (0.9) 0.94 (0.59,1.50) 0.77
Wrist 7 (0.2) 8 (0.1) 0.87 (0.32,2.40) 0.78
Thoracic spine 4 (0.1) 5 (0.1) 0.80 (0.21,2.97) 0.70
Other 26 (0.6) 35 (0.9) 0.74 (0.45,1.23) 0.24
Note: Only first fracture was used for each type of events. One patient could have multiple different types of fractures, so sum of fracture types could be more
than the total of fractures.
Gommans et al. BMC Geriatrics 2013, 13:88 Page 3 of 9
http://www.biomedcentral.com/1471-2318/13/88
(0.83%) assigned B-vitamins and 36 (0.88%) assigned to
placebo (RR 0.94, 95% CI 0.59-1.5) (Table 1). There
was no significant impact of treatment on any other
osteoporotic fracture subtype. A subgroup analysis exclud-
ing the 425 (5.2%) patients who left the study prior to the
2004 inclusion of all fractures as a specified reportable
outcome event, rather than just hospitalised fractures, did
not alter the findings. Compared with placebo, treatment
with B-vitamins was not associated with any significant
difference in the time to first fracture for any osteoporotic
fracture or hip fractures (Figures 1 and 2). A secondary
per protocol on-treatment analysis also showed no impact
of treatment on any osteoporotic fracture outcome after
removal of patients found to be invalid after randomisation
or who had cross-over in treatment during follow-up; either
placebo group patients taking B-vitamins or B-vitamin
group patients stopping their treatment (p = 0.85).
Predictors of osteoporotic fracture
On multivariate analysis independent predictors of any
osteoporotic fracture were female sex (adjusted odds
ratio [OR] 2.58, 95% CI 1.80-3.70), age > 64 years (OR
4.18, 95% CI 2.60-6.72), Western European ethnicity
(OR 3.86, 95% CI 2.52-5.92) and use of anti-
osteoporosis medication at randomization (OR 1.78,
95% CI 1.11-2.86). (Tables 2 and 3). In participants who
volunteered to have their homocysteine levels measured
at baseline (n = 1205), there was no difference between
those with (n = 40; mean tHcy 14.2 ±6.22 μmol/L) or
without subsequent fracture (n = 1165; mean tHcy 14.3
±8.56 μmol/L, p = 0.43). Homocysteine levels at follow-
up were not associated with fracture outcomes in ei-
ther treatment group (Table 4).
Effect of trial medication on homocysteine, folate and
vitamin B12 levels
Of the 1164 (14.3%) study participants who volunteered
to have optional fasting plasma tHcy levels measured at
their final follow-up visit, patients in the B-vitamins
group had a mean 3.8 μmol/L (95% CI 3.1-4.4 μmol/L)
lower tHcy level compared with placebo (10.5 vs. 14.3
μmol/L, p < 0.001). Table 5 compares folate and vitamin
B12 levels between baseline and final follow up visits in
the small subset that volunteered to provide these.
Adverse events
Vitamin B12 deficiency was diagnosed during follow up
in none of the 4089 patients in the B vitamins group
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Figure 1 Kaplan Meier estimates of any osteoporotic fracture outcomes.
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Figure 2 Kaplan Meier estimates of osteoporotic hip fracture outcomes.
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compared with six (0.1%) of 4075 patients in the placebo
group (p = 0.02). Peripheral neuropathy suspected to be
caused by vitamin B6 toxicity was diagnosed in five pa-
tients assigned to B vitamins (0.1%) compared with nine
patients assigned to placebo (0.2%; p = 0.30). There were
no unexpected serious and non-serious adverse events
and there were no significant differences in common ad-
verse effects between the treatment groups (data not
shown).
Discussion
This study did not identify any effect of daily treatment
with B-vitamins for a median of 2.8 years on the overall
incidence of any clinically apparent osteoporotic fracture
or osteoporotic hip fractures during a median of 3.4 years
follow-up in 8,164 patients with recent stroke or TIA
participating in the VITATOPS study.
The study findings of a lack of effect of B vitamins on
osteoporotic fracture are consistent with those of the
Table 2 Baseline characteristics for patients with and without any osteoporotic fracture
Baseline characteristic With any fracture Without fracture p-value
(n = 145) (n = 8019) (log-rank test)
N (%) N (%)
Sex Male 55 (37.9) 5163 (64.4) <.001
Female 90 (62.1) 2854 (35.6
Age <65 yrs 23 (15.9) 4276 (53.3) <.001
> = 65 yrs 122 (84.1) 3743 (46.7)
Ethnicity Western European 105 (78.9) 3171 (42.3) <.001
Oriental 15 (11.3) 1898 (24.7)
South Asian 7 (5.3) 2046 (26.6)
Other 6 (4.5) 566 (7.4)
Oxford Handicap Score > = 3 35 (24.7) 1859 (23.8) 0.18
<3 107 (75.4) 5952 (76.2)
Smoking (ever) Yes 72 (49.7) 3947 (49.9) 0.43
No 73 (50.3) 3966 (50.1)
Alcohol (any) Yes 54 (37.2) 2269 (28.3) 0.20
No 91 (62.8) 5748 (71.7)
Diabetes Yes 24 (16.6) 1875 (23.7) 0.21
No 121 (83.5) 6047 (76.3)
Stroke Yes 28 (19.3) 1254 (15.8) 0.28
No 117 (80.7) 6664 (84.2)
Myocardial infarction Yes 15 (10.3) 583 (7.4) 0.33
No 130 (89.7) 7317 (92.6)
Hypertension Yes 105 (72.4) 5632 (71.1) 0.45
No 40 (27.6) 2285 (28.9)
Depression Yes 16 (16.0) 528 (7.4) 0.003
No 84 (84.0) 6650 (92.6)
Antidepressant medication Yes 24 (16.6) 536 (6.8) <.001
No 121 (83.5) 7332 (93.2)
Corticosteroid medication Yes 3 (2.1) 47 (0.6) 0.011
No 142 (97.9) 7972 (99.4)
Any Osteoporosis Medication * Yes 23 (15.9) 556 (6.9) <.001
No 122 (84.1) 7463 (93.1)
Homocysteine level at baseline † (n = 40) (n = 1165) 0.43
mean (SD) 14.2 (6.2) 14.3 (8.6)
* Including Calcium, Vitamin D, Bisphosphonates and Hormone replacement therapy;
† Not all participants had homocysteine levels measured at Baseline.
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HOPE-2 trial, in which 5522 patients at risk of vascular
disease were treated with B-vitamin therapy for a prolonged
period (mean 5 years) and tHcy was lowered by a similar
amount (3.8 μmol/L in VITATOPS and 3.3 μmol/L in
HOPE-2) compared with placebo [20,21]. Our results in
patients with recent stroke or TIA are at odds however
with the positive findings of the smaller trial of B-vitamins
in disabled Japanese stroke survivors with high tHcy
concentrations [23].
The study’s strengths include the large number of
patients (8164) and their recruitment from a broad
range of centres, countries and ethnic groups; the
randomization process minimising any systematic bias
in treatment allocation; and the blinding of all asses-
sors, clinicians and patients to treatment allocations
minimising observer bias.
The most significant limitation of the study was that it
was underpowered to reliably identify or exclude a modest
Table 3 Any osteoporotic fracture outcomes according to baseline characteristics and treatment group
Baseline characteristic B-Vitamins Placebo p-value P-value for
interaction
(n = 4089) (n = 4075) (log-rank test)
N (%) N (%)
Sex Male 27 (1.0) 28 (1.1) 0.90 0.50
Female 40 (2.7) 50 (3.4) 0.21
Age <65 yrs 12 (0.6) 11 (0.5) 0.90 0.57
> = 65 yrs 55 (2.8) 67 (3.5) 0.28
Ethnicity Western European 48 (2.9) 57(3.5) 0.35 0.65
Oriental 9 (0.9) 6 (0.6) 0.42
South Asian 4 (0.4) 3 (0.3) 0.74
Other 1 (0.4) 5 (1.7) 0.12
Oxford Handicap Score > = 3 14 (1.5) 21 (2.2) 0.18 0.34
<3 51 (1.7) 56 (1.9) 0.63
Smoking (ever) Yes 36 (1.8) 36 (1.8) 0.96 0.30
No 31 (1.5) 42 (2.1) 0.16
Alcohol (any) Yes 26 (2.2) 28 (2.5) 0.71 0.76
No 41 (1.4) 50 (1.7) 0.32
Diabetes Yes 9 (0.9) 15 (1.6) 0.21 0.34
No 58 (1.9) 63 (2.0) 0.62
Stroke Yes 13 (2.1) 15 (2.3) 0.75 0.94
No 54 (1.6) 63 (1.9) 0.38
Myocardial infarction Yes 8 (2.7) 7 (2.3) 0.71 0.49
No 59 (1.6) 71 (1.9) 0.25
Hypertension Yes 48 (1.7) 57 (2.0) 0.40 0.98
No 19 (1.6) 21 (1.8) 0.64
Depression Yes 8 (2.9) 8 (3.0) 0.83 0.51
No 35 (1.0) 49 (1.5) 0.14
Antidepressant medication Yes 11 (4.0) 13 (4.6) 0.67 0.99
No 56 (1.5) 65 (1.8) 0.37
Corticosteroid medication Yes 10 (3.3) 13 (4.7) 0.05 0.98
No 57 (1.5) 65 (1.7) 0.46
Osteoporosis Medication Yes 4 (1.3) 5 (1.8) 0.37 0.62
No 30 (0.8) 31 (0.8) 0.44
Homocysteine < median 10 (3.2) 10 (3.5) 0.77 0.81
(median 12.6 micromol/L) (n = 595)
> =median 8 (2.7) 12 (3.8) 0.53
(n = 610)
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but still clinically important effect of B-vitamins on fracture
rates as there was only a small number of fracture events
resulting in wide 95% confidence intervals for the estimate
of relative risk for any fracture with B-vitamin therapy
compared with placebo - ranging from up to a 38% reduc-
tion to an 18% increase. The low absolute fracture rate
most likely reflects the study population with predom-
inance of men (64%), people of non-Western European
descent (58%) and younger patients (mean age 62.6 years)
who are recognised to have lower rates of fracture [1,27].
Further, most patients with stroke or TIA enrolled in the
trial were functionally independent (75%) and therefore
not at high risk of falls and fractures [28] unlike those
recruited into the positive study of Japanese stroke
survivors [23]. In addition, few patients had pre-existing
osteoporosis at time of randomisation, as identified by low
concurrent use of common osteoporosis preventative and
treatment medications (7%). To reliably detect a modest
but potentially clinically important 15% relative risk re-
duction (RRR) with 80% power in this study population
who appear to be at relatively low risk of fracture would
require a study with over 75,000 participants; more than
nine times that recruited to VITATOPS. Even if a statisti-
cally significant 14% RRR were proven, an absolute risk
reduction of 0.27% (B-vitamins 1.64% and placebo 1.91%)
would equate to a number needed to treat of 370 to
prevent one fracture in 3.4 years.
Adherence to study medication was also incomplete,
although similar between the two treatment groups. This
may have biased the results toward the null hypothesis
and reflects the difficulties inherent in investigator-led
trials conducted with limited peer-reviewed funding [29].
It is possible that the median duration of adherence
to treatment (2.8 years) and follow up (3.4 years) in
VITATOPS was insufficient to identify or exclude any
longer-term effects of therapy with B-vitamins on fracture
risk. However, this is longer than most other published
studies, with the sole exception of the five-year follow-up
in the HOPE-2 trial [17-23].
An additional limitation was that ascertainment of
all fracture outcome events may have been inad-
equate due to incomplete identification of minor
fractures as efforts were focussed on identifying
major vascular events, the primary study outcome.
The relatively high proportion of all fracture out-
comes due to hip fractures (48%) supports this pos-
sibility. Fracture ascertainment may also have been
incomplete prior to prospective reporting of frac-
tures in 2004; however, exclusion of those patients
randomised before 2004 did not alter the findings.
The study results were consistent when analysis was
restricted to participants with hip fractures, an event
that usually results in hospitalisation and is readily
identified.
Table 4 Mean homocysteine concentration at follow up* according to treatment group and fracture outcomes
With fracture mean
(standard deviation)
Without fracture mean
(standard deviation)
Difference,
(95% confidence interval)
P-value
(paired t-test)
Homocysteine (micromol/L
Placebo (n = 584) 15.7 (5.9) (n = 23) 14.2 (6.1) (n = 561) −1.52 (−4.08,1.04) 0.2447
B-Vitamins (n =580) 11.7 (9.6) (n = 18) 10.5 (4.6) (n = 562) −1.17 (−3.46,1.11) 0.3118
* The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not
significant, either (data not shown).
Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.
Table 5 Mean homocysteine, red cell folate and vitamin B12 concentration at baseline and follow up according to
treatment group
Baseline: mean
(standard deviation)
Follow-up: mean
(standard deviation)
Difference
(95% confidence interval)
P-value
(paired t-test)
Homocysteine (micromol/L)
Placebo (n = 463) 13.4 (5.0) 14.3 (5.7) 0.88 (0.40,1.36) <0.001
B-Vitamins (n = 462) 13.5 (6.3) 10.5 (4.2) −3.06 (−3.53,-2.59) <0.001
Red cell Folate (nmol/L)
Placebo (n = 173) 895.0 (466.6) 1135.2 (666.8) 244.8 (151.0,338.7) <0.001
B-Vitamins (n = 183) 959.2 (464.1) 2181.5 (752.3) 1220.0 (1117,1341) <0.001
B 12 (pmol/L)
Placebo (n = 190) 317.6 (140.8) 315.3 (188.9) −2.3 (−26.4,31.1) 0.87
B-Vitamins (n – 196) 322.1 (150.8) 594.7 (271.9) 272.6 (235.2,310.0) <0.001
Note: Only small subsets of patients had homocysteine, folate and vitamin B12 measured at both baseline and follow up.
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Conclusions
In summary this study did not identify any effect of once
daily therapy with folic acid, vitamin B6 and vitamin B12
for a median of 2.8 years on the overall incidence of osteo-
porotic fractures during a median of 3.4 years follow-up in
8,164 patients with recent stroke or TIA participating in
the VITATOPS study.
A modest effect of B-vitamin therapy is not excluded
due to the low numbers of fracture outcome events. Whilst
awaiting the results of further prospective randomized
controlled studies [30] our data suggests no adverse
or favourable effect of homocysteine-lowering with
B-vitamins on fracture outcomes.
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